NuVasive, Inc. (NASDAQ:NUVA) CEO James Christopher Barry Sells 5,000 Shares


NuVasive, Inc. (NASDAQ: NUVAGet a rating) CEO James Christophe Barry sold 5,000 shares of the company in a trade that took place on Wednesday, April 13. The stock was sold at an average price of $58.00, for a total transaction of $290,000.00. Following completion of the transaction, the CEO now owns 50,218 shares of the company, valued at approximately $2,912,644. The transaction was disclosed in a legal filing with the SEC, which is available via this hyperlink.

James Christopher Barry also recently made the following trade(s):

  • On Monday, March 28, James Christopher Barry sold 5,000 NuVasive shares. The stock was sold at an average price of $55.00, for a total transaction of $275,000.00.

Shares of NASDAQ NUVA opened at $59.75 on Friday. The company has a quick ratio of 2.42, a current ratio of 3.99 and a debt ratio of 1.11. NuVasive, Inc. has a 1-year low of $45.45 and a 1-year high of $72.61. The company has a fifty-day moving average price of $53.64 and a 200-day moving average price of $54.23.

NuVasive (NASDAQ: NUVAGet a rating) last announced its results on Wednesday, February 23. The medical device company reported earnings per share of $0.40 for the quarter, missing the Zacks consensus estimate of $0.47 per ($0.07). NuVasive had a positive return on equity of 10.65% and a negative net margin of 5.63%. The company posted revenue of $302.08 million in the quarter, versus analyst estimates of $298.92 million. During the same period a year earlier, the company posted earnings per share of $0.59. NuVasive’s revenue for the quarter increased 3.5% year on year. As a group, sell-side analysts expect NuVasive, Inc. to post earnings per share of 2.16 for the current fiscal year.

Several research analysts have recently weighed in on the stock. Truist Financial assumed coverage for NuVasive shares in a research report on Wednesday. They issued a “buy” rating and a price target of $65.00 for the company. Needham & Company LLC reaffirmed a “buy” rating and set a target price of $64.00 on NuVasive shares in a Thursday, March 24 report. Morgan Stanley lowered its target price on NuVasive shares from $62.00 to $60.00 and set an “equal weight” rating for the company in a Friday, Jan. 7 report. StockNews.com began covering NuVasive shares in a report on Thursday, March 31. They set a “holding” rating for the company. Finally, Wells Fargo & Company began covering NuVasive shares in a Monday, March 28, report. They set an “overweight” rating and a target price of $58.00 for the company. One financial analyst gave the stock a sell rating, seven gave the company a hold rating and seven gave the company a buy rating. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $64.25.

Hedge funds have recently changed their holdings in the company. Exchange Traded Concepts LLC increased its holdings of NuVasive stock by 49.3% in Q4. Exchange Traded Concepts LLC now owns 636 shares of the medical device company valued at $33,000 after buying an additional 210 shares during the period. Rockefeller Capital Management LP increased its holdings of NuVasive shares by 35.3% in Q3. Rockefeller Capital Management LP now owns 1,926 shares of the medical device company valued at $115,000 after purchasing an additional 503 shares during the period. Point72 Hong Kong Ltd increased its holdings of NuVasive shares by 3,406.6% in Q3. Point72 Hong Kong Ltd now owns 2,139 shares of the medical device company valued at $128,000 after buying an additional 2,078 shares during the period. GSA Capital Partners LLP purchased a new equity stake in NuVasive in Q3 valued at approximately $219,000. Finally, Inspire Investing LLC purchased a new equity stake in NuVasive in Q3 valued at approximately $221,000. 98.06% of the shares are currently held by institutional investors.

NuVasive Company Profile (Get a rating)

NuVasive, Inc., a medical technology company, develops, manufactures and sells procedural solutions for spine surgery. It provides surgical access instruments, including the Maxcess integrated split-blade retractor system that enables less invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by improving osseointegration and the biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and a fixation system that facilitates the preservation and restoration of patient alignment.

Further reading



Get news and reviews for NuVasive Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for NuVasive and related companies with MarketBeat.com’s free daily email newsletter.

Comments are closed.